Kymera Therapeutics Announces Early Completion of Phase 2b Trial Enrollment

Kymera Therapeutics (NASDAQ: KYMR) announced the early completion of enrollment for its global Phase 2b trial testing KT-621 in treating severe atopic dermatitis. The topline data is now expected by year-end, ahead of previous guidance. Analysts raised price targets following this news, though an insider stock sale tempered some optimism.

By Eric Volkman, The Motley Fool Sat, June 27, 2026 at 2:05 AM GMT+3 3 min read · Yahoo Finance · June 26, 2026, 23:05 UTC

Tickers: $KYMR $NVDA

Topics: analyst upgrades biotech insider transactions stock movement

Read the full article at Yahoo Finance

More World news

Allstate Announces Quarterly Dividend of $1.08 Per Share Seeking Alpha · November 12, 2026, 18:01 UTC
Pinnacle Bankshares Increases Quarterly Dividend to $0.35 Per Share Seeking Alpha · November 12, 2026, 18:02 UTC
Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC
Equinor Raises Production Guidance and Establishes Share Buyback Framework Motley Fool · November 12, 2026, 18:00 UTC
Flex Announces Strategic Spin-off of Cloud and Power Infrastructure Segment into Axiom Motley Fool · November 12, 2026, 18:00 UTC
Extreme Networks Raises Fiscal 2027 Revenue Guidance Amid Strong SaaS Growth and Large Enterprise Bookings Motley Fool · November 12, 2026, 18:00 UTC
Federal Reserve to Designate October 2027 Meeting as Nonvoting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Pelagos Insurance Capital Reports Mixed Q3 2026 Results with Revenue Beat and EPS Miss Seeking Alpha · November 12, 2026, 18:01 UTC
Aline Accounting Partners Secures $206 Million in Financing Led by Square Nine Capital PR Newswire · November 12, 2026, 18:00 UTC
Egan-Jones November 2026 Report Shows Soft CLO Issuance Amid Improving Credit Metrics PR Newswire · November 12, 2026, 18:00 UTC